title: Terlipressin facilitates transport of septic patients treated with norepinephrine.
abstract: BACKGROUND
  Transport of hemodynamic unstable septic patients for diagnostic or therapeutic interventions outside the intensive care unit is complex but sometimes contributes to increasing the chance of survival.
  
  
  OBJECTIVE
  To report our experience with terlipressin treatment for facilitation of transport to distant facilities for diagnostic or therapeutic procedures in septic patients treated with norepinephrine.
  
  
  METHODS
  We conducted a retrospective analysis of the records of our ICU, identifying the patients with septic shock who required norepinephrine for hemodynamic support.
  
  
  RESULTS
  Terlipressin was given to 30 septic shock patients (15 females and 15 males) who were on high dose norepinephrine (10 microg/min or more) in order to facilitate their transport outside the ICU. The dose of terlipressin ranged from 1 to 4 mg, with a mean of 2.13+/-0.68 mg. The dose of norepinephrine needed to maintain systolic blood pressure above 100 mmHg decreased following terlipressin administration, from 21.9+/-10.4 microg/min (range 5-52 microg/min) to 1.0+/-1.95 (range 0-10) (P < 0.001). No patients required norepinephrine dose adjustment during transport. No serious complications or overshoot in blood pressure values were observed following terlipressin administration. Acrocyanosis occurred only in eight patients receiving more than 1 mg of the drug. The overall mortality rate was 50%.
  
  
  CONCLUSIONS
  Our data suggest that terlipressin is effective in septic shock. Because it is long-acting and necessitates less titration it might be indicated for patient transportation.
authors.affiliation: Department of Critical Care, Division of Anesthesiology and Critical Care, Soroka University Hospital, Beer Sheva, Israel. motiklein@yahoo.com
authors.forename: Moti
authors.initials: M
authors.lastname: Klein
authors.forename: Natan
authors.initials: N
authors.lastname: Weksler
authors.forename: Avraham
authors.initials: A
authors.lastname: Borer
authors.forename: Leonid
authors.initials: L
authors.lastname: Koyfman
authors.forename: Jerome
authors.initials: J
authors.lastname: Kesslin
authors.forename: Gabriel M
authors.initials: GM
authors.lastname: Gurman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008236:Lypressin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000008:administration & dosage*; D012189:Retrospective Studies; D012772:Shock, Septic / Q000188:drug therapy*; D000077585:Terlipressin; D014187:Transportation of Patients / Q000379:methods*; D014662:Vasoconstrictor Agents / Q000008:administration & dosage*
chemical_list: D000959:Antihypertensive Agents; D014662:Vasoconstrictor Agents; D008236:Lypressin; D000077585:Terlipressin; D009638:Norepinephrine